Beam Therapeutics Inc 2026年季度报告

For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Registrant’s telephone number, including area code: (857) 327-8775 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☒ The number of shares of registrant’s common stock outstanding as of April 30, 2026 was 102,879,214. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the ExchangeAct. Such forward-looking statements reflect, among other things: •our current expectations and anticipated results of operations;•our expectations regarding the timing, progress and results of our clinical trials, including our Phase 1/2 clinical trialdesigned to assess the safety and efficacy of risto-cel for the treatment of sickle cell disease, our Phase 1/2 clinical trialdesigned to assess the safety and efficacy of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency, our Phase1/2 clinical trial designed to assess the safety and efficacy of BEAM-301 for the treatment of glycogen storage diseasetype 1a, and our Phase 1 healthy volunteer clinical trial of BEAM-103;•our ability to file a biologics license application within a certain time period, and to demonstrate to applicableregulators that our product candidates are safe and effective and that their benefits outweigh known and potential risksfor the intended patient population;•our expectations regarding the initiation, timing, progress and results of our research and development programs andpreclinical studies, including with respect to BEAM-304 for the treatment of phenylketonuria;•our ability to develop and maintain a sustainable portfolio of product candidates;•our ability to develop life-long, curative, precision genetic medicines for patients through base editing;•our ability to create a hub for partnering with other companies;•our plans for preclinical studies for product candidates in our pipeline;•our ability to advance any product candidates that we may develop and successfully complete any clinical trials orpreclinical studies, including the manufacture of any such product candidates;•our ability to pursue a broad suite of clinically validated delivery modalities;•our expectations regarding our ability to generate additional novel lipid nanoparticles that we believe could acceleratenovel nonviral delivery of gene editing or other nucleic acid payloads to tissues beyond the liver and our ability toexpand the reach of our programs;•the scope of protection we are able to establish and maintain for intellectual property rights covering our productcandidates and technology;•developments related to our competitors and our industry;•the expected timing, progress and success of our collaborations with third parties, including any future payments wemay receive under our collaboration and license agreements,and our ability to identify and enter into future licenseagreements and collaborations;•developments related to base editing technologies;•our ability to successfully develop our delivery modalities and obtain and maintain approval for our product candidates;•our ability to successfully maintain a commercial-scale current Good Manufacturing Practice, or cGMP, manufacturin